- Jul 2018
-
europepmc.org europepmc.org
-
On 2017 Nov 24, Ryszard Grenda commented:
Thank you; the comment is valid; apologies from the authors for mistake in the review.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY. -
On 2017 Nov 18, Mark Milton commented:
This article states that "Eculizumab is a humanized monoclonal antibody directed against the C5a component of the complement system, and this binding leads to blockade of the C5b-9 membrane attack complex while the other functions of the complement are maintained."
This is incorrect. Eculizumab, specifically binds to the C5, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
On 2017 Nov 18, Mark Milton commented:
This article states that "Eculizumab is a humanized monoclonal antibody directed against the C5a component of the complement system, and this binding leads to blockade of the C5b-9 membrane attack complex while the other functions of the complement are maintained."
This is incorrect. Eculizumab, specifically binds to the C5, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY. -
On 2017 Nov 24, Ryszard Grenda commented:
Thank you; the comment is valid; apologies from the authors for mistake in the review.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-